HeartBeam, Inc., a cardiac technology company that has developed the first and only 3D vector electrocardiogram (VECG) platform intended for patient use at home, announced it has submitted a 510(k) application to the US Food and Drug Administration (FDA) for its HeartBeam AIMIGo System.
HeartBeam has developed the HeartBeam AIMIGo System, a personal, portable and easy-to-use VECG solution to assist patients and their clinicians in assessing cardiac symptoms. HeartBeam
